SCHEMBL16682880

SCHEMBL16682880

Cc1nc(-c2cccc(Cl)c2)nc2c1SCC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDH1 O75874 1/20 0.40
▸ NR1I3 Q14994 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CHRNB4 P30926 1/20 0.38
▸ CHRNA3 P32297 1/20 0.38
▸ HRH4 Q9H3N8 1/20 0.38
▸ CYP19A1 P11511 1/20 0.37
▸ MAPK10 P53779 1/20 0.36
▸ MAPT P10636 2/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ IDO1 P14902 1/20 0.36
▸ TP53 P04637 2/20 0.36
▸ ABCB1 P08183 1/20 0.35
▸ ABCC1 P33527 1/20 0.35
▸ ABCG2 Q9UNQ0 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15662341 0.84 CYP19A1 (0.40) IDH1NR1I3CHRNB4CHRNA3HRH4
SCHEMBL23586239 0.77 NR1I3 (0.39) IDH1NR1I3CHRNB4CHRNA3HRH4
SCHEMBL15659115 0.76 PDE4B (0.42) IDH1NR1I3CHRNB4CHRNA3HRH4
SCHEMBL15947979 0.74 PDE4D (0.44) IDH1NR1I3KMT2ACHRNB4CHRNA3
SCHEMBL23586143 0.74 NR1I3 (0.37) IDH1NR1I3KMT2ACHRNB4CHRNA3
SCHEMBL23586226 0.70 NR1I3 (0.40) IDH1NR1I3CHRNB4CHRNA3HRH4
SCHEMBL10589866 0.70 IDO1 (0.57) IDH1NR1I3HRH4CYP19A1NPC1
SCHEMBL6076679 0.66 KDM4E (0.49) NR1I3CHRNB4CHRNA3MAPTNPC1
SCHEMBL5732452 0.66 KDM4E (0.49) NR1I3CHRNB4CHRNA3MAPTNPC1
SCHEMBL15662301 0.66 CHRNB4 (0.37) IDH1NR1I3CHRNB4CHRNA3HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9221843-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2015-12-29 — — US disclosed
US-20150119362-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2015-04-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119362-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C IDH1 1604/4885NR1I3 1994/4885KMT2A 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback